Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1291 to 1305 of 2026 results for nice guidelines

  1. National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)

    NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .

  2. Changes to NICE's cost-effectiveness thresholds

    NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments. This follows the government’s decision to increase the thresholds that NICE can use in technology appraisals to £25,000 to £35,000 per quality-adjusted life year gained.

  3. Referral criteria for people with suspected axial spondyloarthritis:- What are the optimal referral criteria for people with suspected axial spondyloarthritis?

    cost per quality-adjusted life year (QALY) gained (the NICE economic model developed for this guideline could easily be...

  4. Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment (HTG760)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.

  5. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  6. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

  7. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  8. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.

  9. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

  10. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    Surgery for uterine prolapse Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last updated April...

  11. Sepsis (QS161)

    November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.

  12. The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma

  13. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

  14. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

  15. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.